The global post-operative nausea and vomiting (PONV) market is witnessing substantial growth due to the increasing number of surgical procedures, rising awareness regarding post-surgical care, and advancements in anti-emetic therapies. PONV remains one of the most common complications following surgery and anesthesia, affecting a significant percentage of patients worldwide. According to industry estimates, the global PONV market was valued at US$ 2.1 Bn in 2022 and is projected to reach US$ 4.0 Bn by the end of 2031, expanding at a CAGR of 7.4% from 2023 to 2031.

Post-operative nausea and vomiting can severely impact patient recovery and satisfaction. The condition often leads to prolonged hospital stays, additional healthcare costs, delayed discharge, and increased discomfort for patients. As healthcare providers focus more on improving patient outcomes and enhancing surgical recovery experiences, the demand for effective PONV treatment solutions is expected to rise steadily over the forecast period.

Gain a preview of important insights from our Report in this sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2969

Market Overview

Post-operative nausea and vomiting refers to nausea and vomiting that occur after surgical procedures, typically within the first 24 hours following anesthesia. It is considered one of the most unpleasant complications associated with surgery and affects nearly 30% of all surgical patients and up to 80% of high-risk patients.

The growing prevalence of chronic diseases such as cancer, cardiovascular disorders, and gastrointestinal conditions has significantly increased the volume of surgeries conducted globally. Cancer-related surgeries, in particular, are major contributors to the increasing incidence of PONV. According to the World Health Organization (WHO), cancer accounts for over 10 million deaths annually, resulting in a growing number of surgical interventions worldwide.

Additionally, the increasing prevalence of anemia is contributing to the growth of the PONV market. Reports suggest that around 1.92 billion people suffered from anemia in 2021. Anemic patients are more susceptible to post-operative complications, including nausea and vomiting, thereby driving the need for advanced therapeutic solutions.

Pharmaceutical companies are actively investing in the development of innovative anti-emetic drugs, including serotonin antagonists, dopamine antagonists, steroids, and NK-1 receptor antagonists, to improve post-operative care outcomes.

Key Drivers of Market Growth

Increase in Surgical Procedures Worldwide

One of the primary factors fueling the growth of the PONV market is the sharp rise in the number of surgeries performed globally. Improvements in healthcare infrastructure, expanding access to surgical care, and the increasing burden of chronic diseases are contributing to higher surgical volumes.

Major surgeries such as mastectomy, thoracotomy, orthopedic procedures, and cancer surgeries are often associated with a higher risk of post-operative complications, including nausea and vomiting. As surgical interventions become more common, the demand for effective PONV treatment therapies continues to rise.

Growing Burden of Post-Operative Complications

Patients with co-morbidities such as renal disease, pulmonary disorders, neurological conditions, and hepatic ailments are at increased risk of developing post-operative complications. Conditions such as anemia and perioperative hypoalbuminemia further elevate the likelihood of PONV occurrence.

Emergency surgeries also contribute to increased complications such as myocardial infarction, pneumonia, stroke, and bleeding, which often require prolonged hospitalization and additional treatment procedures. Consequently, healthcare providers are prioritizing preventive care and anti-emetic therapies to reduce recovery complications.

Rising Awareness About Post-Surgical Care

Healthcare institutions and governments across various countries are promoting awareness regarding post-surgical complications and recovery management. Institutional protocols for managing nausea and vomiting after surgery are becoming more standardized, particularly in developed economies.

Patients are increasingly willing to spend more on treatments that improve recovery experiences and minimize discomfort after surgeries. This trend is positively impacting the adoption of advanced PONV drugs and therapies.

Expansion of Healthcare Infrastructure

Emerging economies in Asia Pacific, Latin America, and the Middle East are witnessing rapid improvements in healthcare infrastructure. Increased hospital investments, better access to healthcare facilities, and growing medical tourism are expected to create favorable conditions for market expansion.

Key Players and Industry Leaders

The global PONV market is highly competitive, with the presence of several multinational and regional pharmaceutical companies. These companies are focusing on strategic collaborations, drug approvals, product innovations, and geographic expansion to strengthen their market position.

Some of the leading companies operating in the global PONV market include:

• Acacia Pharma
• F. Hoffmann-La Roche AG
• Novartis AG
• Ani Pharmaceuticals, Inc.
• Camurus AB
• Sanofi S.A.
• Helsinn Holding S.A.
• Eisai Corporation
• GlaxoSmithKline Corporation
• Merck and Co.

These organizations are actively investing in research and development activities to launch innovative treatment therapies aimed at improving patient outcomes and minimizing post-surgical complications.

Recent Developments

The PONV market has witnessed several notable developments in recent years:

• In April 2022, Evoke Pharma, Inc. received new drug product exclusivity from the U.S. FDA for Gimoti (metoclopramide) nasal spray.
• In February 2022, Acacia Pharma obtained U.S. FDA approval for Barhemsys, an intravenous amisulpride formulation used to treat PONV in patients who failed prior anti-emetic treatments.
• In September 2020, Sandoz, a division of Novartis AG, launched generic Fosaprepitant, an anti-emetic therapy designed to prevent chemotherapy-induced nausea and vomiting.

These product approvals and launches are expected to strengthen the treatment landscape and improve patient access to advanced therapies.

Key Trends for the Future

Several important trends are expected to shape the future of the PONV market:

• Growing adoption of outpatient and minimally invasive surgeries
• Increasing demand for rapid recovery protocols
• Rising focus on patient-centered healthcare
• Expansion of advanced anti-emetic drug portfolios
• Greater emphasis on personalized treatment approaches
• Increasing healthcare expenditure in emerging economies
• Technological integration in post-operative monitoring systems

New Opportunities and Challenges

Opportunities

The increasing demand for minimally invasive surgeries and ambulatory surgical centers is expected to create significant opportunities for PONV treatment providers. Ambulatory surgeries require rapid patient recovery and discharge, increasing the importance of effective nausea and vomiting management.

Furthermore, advancements in personalized medicine and targeted therapies are likely to enhance treatment efficacy and patient outcomes in the coming years.

Emerging markets such as India, China, Brazil, and Southeast Asian countries also present strong growth potential due to expanding healthcare access and rising surgical procedures.

Challenges

Despite strong growth prospects, the market faces certain challenges. Strict regulatory guidelines regarding anesthesia drugs and infusion therapies may limit the approval of certain treatments.

Additionally, side effects associated with anti-emetic medications and the high cost of advanced therapies may restrict adoption in low-income regions.

Healthcare providers also face challenges in accurately identifying high-risk patients and implementing standardized preventive treatment protocols across healthcare systems.

Market Trends & Innovations

The PONV market is witnessing several technological and therapeutic advancements that are transforming patient care.

Development of Combination Therapies

Pharmaceutical companies are increasingly focusing on combination therapies that target multiple receptors responsible for nausea and vomiting. These therapies offer improved efficacy compared to single-drug treatments.

Rise in NK-1 Receptor Antagonists

NK-1 receptor antagonists are gaining popularity due to their effectiveness in reducing severe post-operative nausea and vomiting episodes. These therapies are expected to witness strong adoption during the forecast period.

Increased Adoption of Non-Pharmacologic Treatments

Healthcare providers are exploring non-pharmacologic approaches such as acupuncture, aromatherapy, and enhanced recovery protocols to complement traditional anti-emetic therapies.

Digital Healthcare Integration

Hospitals are increasingly utilizing digital monitoring systems and patient management platforms to track recovery outcomes and identify complications early, improving the effectiveness of post-operative care.

Buy this Premium Research Report and explore vital industry trends – https://www.transparencymarketresearch.com/checkout.php?rep_id=2969&ltype=S

Future Outlook

The future of the post-operative nausea and vomiting market appears highly promising due to the increasing global surgical burden and continuous advancements in pharmaceutical therapies.

North America is expected to maintain its dominant position owing to the high number of surgeries conducted annually, strong healthcare infrastructure, and greater awareness regarding post-operative care.

Europe is also anticipated to witness robust growth due to the large surgical patient population and increasing adoption of advanced anti-emetic therapies.

Meanwhile, Asia Pacific is projected to emerge as the fastest-growing region during the forecast period, driven by improving healthcare systems, rising medical tourism, and increasing healthcare investments.

With continued innovation, regulatory approvals, and rising patient awareness, the global PONV market is expected to experience sustained growth through 2031.

Market Segmentation

By Treatment Type

• Serotonin Antagonists
• Steroids
• Dopamine Antagonists
• NK-1 Receptor Antagonists
• Non-pharmacologic Treatment
• Others

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies & Drug Stores

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Important FAQs with Answers

How big was the post-operative nausea and vomiting (PONV) market in 2022?

The global PONV market was valued at US$ 2.1 Bn in 2022.

What is the projected market size by 2031?

The market is expected to reach US$ 4.0 Bn by the end of 2031.

What is the expected CAGR during the forecast period?

The market is projected to expand at a CAGR of 7.4% from 2023 to 2031.

What factors are driving the growth of the market?

Key growth drivers include the rising number of surgeries, increasing post-operative complications, growing prevalence of chronic diseases, and advancements in anti-emetic therapies.

Which region dominates the global PONV market?

North America currently dominates the global market due to the high number of surgical procedures and strong healthcare infrastructure.

Which distribution channel held the largest market share?

Hospital pharmacies accounted for the largest market share in 2022.

Who are the leading players in the market?

Major players include Acacia Pharma, Novartis AG, Sanofi S.A., and Merck and Co. among others.

More Related Reports –

Kidney Cancer Drugs Market: https://www.transparencymarketresearch.com/kidney-cancer-drugs-market.html

Sarcopenia Treatment Market: https://www.transparencymarketresearch.com/sarcopenia-treatment-market.html

Acromegaly Treatment Market: https://www.transparencymarketresearch.com/acromegaly-treatment-market.html

Abortion Drugs Market: https://www.transparencymarketresearch.com/abortion-drugs-market.html

About Us Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com